List view / Grid view
25 October 2024 | By Simon Lovestone (Johnson & Johnson)
In this Q&A, Simon Lovestone, Vice President, Global Head, Neuroscience Discovery and Translational Science at Johnson & Johnson, shares how they are leveraging the A/T/N biomarker framework to achieve breakthroughs in Alzheimer’s disease research, in an aim to alter disease progression before daily life is significantly affected.
23 September 2021 | By Victoria Rees (Drug Target Review)
In a new study, researchers at Brigham and Women’s Hospital, US, successfully developed stem cell-derived neuronal profiles from individual patients. Here, Drug Target Review’s Victoria Rees explores the findings and how these new models can help to advance precision and personalised medicine.
11 January 2023 | By Izzy Wood (Drug Target Review)
In this article, Drug Target Review’s Izzy Wood reviews some of the latest Alzheimer's disease research, highlighting the progress that has been made toward new, more unique therapeutic strategies against Alzheimer’s.
31 August 2023 | By Tony Portelli (Drug Target Review)
In the pursuit of a remedy for Alzheimer's disease, a frontier in medical science is illuminating a glimmer of hope. Stem cell therapies have already demonstrated their prowess in treating diverse cancers and ailments linked to the blood and immune system.
18 April 2023 | By Ria Kakkad (Drug Target Review)
Using rodent models, the researchers emphasized the potential of newly generated neurons in adulthood to serve as therapy for addressing the functional deficits and pathology associated with Alzheimer's disease.
31 August 2021 | By Victoria Rees (Drug Target Review)
Dr Ronald G Crystal, Professor and Chairman of the Department of Genetic Medicine, Weill Cornell Medical College, spoke to Drug Target Review’s Fraser Owen about his research into Alzheimer’s disease and why gene therapies represent a promising area of research for neurodegenerative conditions.
30 June 2023 | By Izzy Wood (Drug Target Review)
Individuals with higher levels of lean muscle may have a reduced risk of developing Alzheimer's disease. While further research is needed to understand the underlying biological pathways and implications for clinical practice, these findings shed light on the potential role of lean muscle in protecting brain health.
12 July 2021 | By Anna Begley (Drug Target Review)
US researchers have identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that could be used against these targets.
2 August 2023 | By Taylor Mixides (Drug Target Review)
Promising preliminary research reveals a novel vaccine targeting an Alzheimer’s disease-related protein successfully eliminated toxic cells in mice afflicted with the condition.
12 October 2021 | By Anna Begley (Drug Target Review)
Scientists have identified the OAS1 gene as a risk factor for both Alzheimer's disease and COVID-19, suggesting potential drug targets.
23 April 2021 | By Victoria Rees (Drug Target Review)
Oral doses of a new drug named CA administered to mouse models led to improvements in Alzheimer's disease, including memory.
14 November 2023 | By Drug Target Review
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
11 September 2020 | By Monika Schmidt (University of Hradec Kralove), Sheraz Gul (Fraunhofer Institute)
Although many potential targets have been identified for Alzheimer’s disease (AD), there is no effective treatment for this debilitating condition. In this article, Monika Schmidt and Sheraz Gul delve into the key proteins implicated in AD and suggest how phenotypic assays could aid in AD drug discovery.
11 April 2025 | By Drug Target Review
Researchers at UTHealth Houston have initiated a new stem cell therapy trial aimed at reducing neuroinflammation to prevent Alzheimer's disease before symptoms emerge, an approach that could revolutionise treatment strategies, offering new hope for at-risk individuals.
2 April 2025 | By Drug Target Review
Porosome Therapeutics has made a groundbreaking discovery in Alzheimer’s research by targeting the disease’s molecular causes, focusing on restoring secretory and metabolic functions. This approach could not only slow progression but potentially reverse early-stage pathology.
